High Energy Intake Induced Overexpression of Transcription Factors and Its Regulatory Genes Involved in Acceleration of Hepatic Lipogenesis: A Rat Model for Type 2 Diabetes

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2019 Oct 2

PMID 31569751

Citations 6

Authors

Suresh P Khadke

Aniket A Kuvalekar

Abhay M Harsulkar

Nitin Mantri

Affiliations

Soon will be listed here.

Abstract

Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by impaired insulin action and its secretion. The objectives of the present study were to establish an economical and efficient animal model, mimicking pathophysiology of human T2DM to understand probable molecular mechanisms in context with lipid metabolism. In the present study, male Wistar rats were randomly divided into three groups. Animals were fed with high fat diet (HFD) except healthy control (HC) for 12 weeks. After eight weeks, intra peritoneal glucose tolerance test was performed. After confirmation of glucose intolerance, diabetic control (DC) group was injected with streptozotocin (STZ) (35 mg/kg b.w., i.p.). HFD fed rats showed increase ( ≤ 0.001) in glucose tolerance and HOMA-IR as compared to HC. Diabetes rats showed abnormal ( ≤ 0.001) lipid profile as compared to HC. The hepatocyte expression of transcription factors and and their target genes were found to be upregulated, while and expressions were downregulated as compared to the HC. A number of animal models have been raised for studying T2DM, but the study has been restricted to only the biochemical level. The model is validated at biochemical, molecular and histopathological levels, which can be used for screening new therapeutics for the effective management of T2DM.

Citing Articles

Oleanolic acid attenuates obesity through modulating the lipid metabolism in high-fat diet-fed mice.

Zhang G, Zhang H, Dong R, Zhao H, Li J, Yue W Food Sci Nutr. 2024; 12(10):8243-8254.

PMID: 39479652 PMC: 11521747. DOI: 10.1002/fsn3.4408.

The potential molecular mechanism underlying gypenoside amelioration of atherosclerosis in ApoE mice: A multi-omics investigation.

Ju X, Liu Y, Wang Y, Sui G, Ma Y, Cao H Heliyon. 2024; 10(8):e29164.

PMID: 38644881 PMC: 11031777. DOI: 10.1016/j.heliyon.2024.e29164.

High-Density Lipoproteins and Cardiovascular Disease: The Good, the Bad and the Future.

Julve J, Escola-Gil J Biomedicines. 2021; 9(8).

PMID: 34440061 PMC: 8389556. DOI: 10.3390/biomedicines9080857.

Protective Effect of Jiang Tang Xiao Ke Granules against Skeletal Muscle IR via Activation of the AMPK/SIRT1/PGC-1 Signaling Pathway.

Bai Y, Zuo J, Fang X, Ma R, Tian T, Mo F Oxid Med Cell Longev. 2021; 2021:5566053.

PMID: 34326919 PMC: 8277912. DOI: 10.1155/2021/5566053.

Effects of Bile Acids on Growth Performance and Lipid Metabolism during Chronic Heat Stress in Broiler Chickens.

Yin C, Tang S, Liu L, Cao A, Xie J, Zhang H Animals (Basel). 2021; 11(3).

PMID: 33673472 PMC: 7997420. DOI: 10.3390/ani11030630.

References

. Standards of medical care in diabetes--2009. Diabetes Care. 2009; 32 Suppl 1:S13-61. PMC: 2613589. DOI: 10.2337/dc09-S013. View

Beagley J, Guariguata L, Weil C, Motala A . Global estimates of undiagnosed diabetes in adults. Diabetes Res Clin Pract. 2013; 103(2):150-60. DOI: 10.1016/j.diabres.2013.11.001. View

Islam M, Wilson R . Experimentally induced rodent models of type 2 diabetes. Methods Mol Biol. 2012; 933:161-74. DOI: 10.1007/978-1-62703-068-7_10. View

Garvey W, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A . Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003; 52(2):453-62. DOI: 10.2337/diabetes.52.2.453. View

Chen L, Frister A, Wang S, Ludwig A, Behr H, Pippig S . Interaction of vascular smooth muscle cells and monocytes by soluble factors synergistically enhances IL-6 and MCP-1 production. Am J Physiol Heart Circ Physiol. 2009; 296(4):H987-96. DOI: 10.1152/ajpheart.01158.2008. View

Pickup J, Mattock M, Chusney G, Burt D . NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997; 40(11):1286-92. DOI: 10.1007/s001250050822. View

Horton J, Goldstein J, Brown M . SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002; 109(9):1125-31. PMC: 150968. DOI: 10.1172/JCI15593. View

Zhang M, Lv X, Li J, Xu Z, Chen L . The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res. 2009; 2008:704045. PMC: 2613511. DOI: 10.1155/2008/704045. View

Arkan M, Hevener A, Greten F, Maeda S, Li Z, Long J . IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005; 11(2):191-8. DOI: 10.1038/nm1185. View

10.

Skovso S . Modeling type 2 diabetes in rats using high fat diet and streptozotocin. J Diabetes Investig. 2014; 5(4):349-58. PMC: 4210077. DOI: 10.1111/jdi.12235. View

11.

Saltiel A, Olefsky J . Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996; 45(12):1661-9. DOI: 10.2337/diab.45.12.1661. View

12.

Veerkamp J, van Moerkerk H . Fatty acid-binding protein and its relation to fatty acid oxidation. Mol Cell Biochem. 1993; 123(1-2):101-6. DOI: 10.1007/BF01076480. View

13.

Kim E, Lee J, Kim S, Jo M, Hwang J, Bae S . Serum Triglyceride Levels and Cardiovascular Disease Events in Koreans. Cardiology. 2015; 131(4):228-35. DOI: 10.1159/000380941. View

14.

Cai D, Yuan M, Frantz D, Melendez P, Hansen L, Lee J . Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005; 11(2):183-90. PMC: 1440292. DOI: 10.1038/nm1166. View

15.

Luo J, Quan J, Tsai J, Hobensack C, Sullivan C, Hector R . Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Metabolism. 1998; 47(6):663-8. DOI: 10.1016/s0026-0495(98)90027-0. View

16.

Lebovitz H, Banerji M . Treatment of insulin resistance in diabetes mellitus. Eur J Pharmacol. 2004; 490(1-3):135-46. DOI: 10.1016/j.ejphar.2004.02.051. View

17.

Guariguata L, Whiting D, Hambleton I, Beagley J, Linnenkamp U, Shaw J . Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014; 103(2):137-49. DOI: 10.1016/j.diabres.2013.11.002. View

18.

Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2):227-39. DOI: 10.1161/01.CIR.0000133317.49796.0E. View

19.

Rerup C . Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol Rev. 1970; 22(4):485-518. View

20.

Unger R, Clark G, Scherer P, Orci L . Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta. 2009; 1801(3):209-14. DOI: 10.1016/j.bbalip.2009.10.006. View